Debiopharm Group™ (Debiopharm) has announced that Dr. Reddy’s Laboratories Ltd. has launched Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3.
Under the terms of the agreement, Dr. Reddy’s acquires exclusive marketing and sales rights for Pamorelin® LA Depot in India.
The product is exported in bulk from Debio Recherche Pharmaceutique (Debio R.P.) to Dr. Reddy’s.
Pamorelin® LA will be made available primarily to urologists and oncologists across India.
‘We recognize the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin® LA to Indian patients’, said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.
Mauvernay continued, ‘This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy’s over the years.’
Dr. Reddy’s and Debiopharm share the same vision to bring high-quality and safe ethical products to the highest number of patients suffering from serious diseases in India.